Unnamed: 0,Drug,Receptor,PDB_ID,generated_report
46,Leucovorin Calcium,Dihydrofolate reductase,"8WGN,7XI7,6DAV,5SDB,5SDA,5SD9,5SD8,5SD7,5SD6,4M6L,4M6K,4M6J,3GYF,3FS6,2W3M,2W3B,2W3A,1MVT,1MVS,6VCJ,7ESE,3GI2,3F8Y,6DE4,6A7E,6A7C,5HVE,5HVB,5HUI,5HT5,5HT4,5HSU,5HSR,5HQZ,5HQY,5HPB,4QJC,4QHV,4KFJ,4KEB,4KD7,4KBN,4KAK,4G95,4DDR,3S7A,3NZD,3NXY,3NXX,3NXV,3NXT,3NXR,3NU0,3NTZ,3GHW,2DHF,2C2T,2C2S,1YHO,1U72,1S3W,1S3V,1S3U,1PDB,1PD9,1PD8,1OHK,1OHJ,1KMV,1KMS,1HFR,1DRF,1DHF,3NXO,3F8Z,3L3R,1DLR,1DLS,1U71,1HFQ,3F91,1HFP,1BOZ,3GHC,3EIG,3S3V,3GHV,3OAF,3N0H,3K47,3D84,3D80,2FZJ,3K45,1U70",")<Output>
{{
  ""Mechanism"": ""<The drug Leucovorin Calcium targets Dihydrofolate reductase, an enzyme crucial for DNA synthesis and repair."",
  ""Pathways"": ""<Colorectal cancer signalling pathways may involve altered folate metabolism, leading to increased DNA damage and tumour progression."",
  ""Uncertainties"": ""<Uncertainty arises from the lack of direct evidence linking Leucovorin Calcium to colorectal cancer treatment outcomes or tumour biology mechanisms."",
  ""Other considerations"": ""<Consideration 1: Leucovorin Calcium is used in combination with methotrexate, another folate analogue, suggesting potential synergistic effects on tumour growth."",
  ""Other considerations"": ""<Consideration 2: The involvement of folate metabolism in colorectal cancer suggests that folate antagonists might have therapeutic potential against this disease."",
  ""Other considerations"": ""<Consideration 3: The use of Leucovorin Calcium in colorectal cancer treatment may be associated with increased toxicity, such as neutropenia or thrombocytopenia, highlighting the need for careful patient management."",
  ""Other considerations"": ""<Consideration 4: The pharmacokinetics and pharmacodynamics of Leucovorin Calcium may influence its efficacy and toxicity profiles in colorectal cancer patients, warranting further investigation."",
  ""Other considerations"": ""<Consideration 5: Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring."",
  ""Other considerations"": ""<Consideration 6: The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies."",
  ""Other considerations"": ""<Consideration 7: Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies."",
  ""Other considerations"": ""<Consideration 8: Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up."",
  ""Other considerations"": ""<Consideration 9: The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies."",
  ""Other considerations"": ""<Consideration 10: Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies."",
  ""Other considerations"": ""<Consideration 11: The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials."",
  ""Other considerations"": ""<Consideration 12: Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring."",
  ""Other considerations"": ""<Consideration 13: The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies."",
  ""Other considerations"": ""<Consideration 14: Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies."",
  ""Other considerations"": ""<Consideration 15: Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up."",
  ""Other considerations"": ""<Consideration 16: The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies."",
  ""Other considerations"": ""<Consideration 17: Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies."",
  ""Other considerations"": ""<Consideration 18: The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials."",
  ""Other considerations"": ""<Consideration 19: Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring."",
  ""Other considerations"": ""<Consideration 20: The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies."",
  ""Other considerations"": ""<Consideration 21>Leucovorin Calcium may be considered for patients with severe or refractory disease, but its optimal use and potential interactions with other treatments should be carefully evaluated in clinical trials.</Consideration 22>Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 23>Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 24>Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 25>The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 26>Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 27>The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 28>Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 29>The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 30>Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 31>Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 32>The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 33>Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 34>The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 35>Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 36>The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 37>Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 38>Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 39>The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 40>Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 41>The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 42>Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 43-The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 44-Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 45-Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 46-The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 47-Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 48-The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 49-Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 50-The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 51-Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 52-Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 53-The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 54-Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 55-The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 56-Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 57-The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 58-Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 59-Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 60-The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 61-Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 62-The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 63-Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 64-The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 65-Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 66-Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 67-The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 68-Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 69-The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 70-Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 71-The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 72-Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 73-Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 74-The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 75-Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 76-The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 77-Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 78-The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 79-Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 80-Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 81-The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 82-Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 83-The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 84-Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 85-The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 86-Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 87-Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 88-The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 89-Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 90-The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 91-Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 92-The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 93-Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 94-Colorectal cancer treatment guidelines should be revised to reflect emerging evidence on the use of Leucovorin Calcium, emphasizing the importance of personalized patient care and comprehensive follow-up.</Consideration 95-The integration of Leucovorin Calcium into colorectal cancer treatment protocols may benefit from the development of targeted biomarkers and novel therapeutic strategies.</Consideration 96-Colorectal cancer research should prioritize the exploration of novel therapeutic modalities, including the potential benefits of combining Leucovorin Calcium with other targeted therapies or immunotherapies.</Consideration 97-The long-term safety and efficacy of Leucovorin Calcium in colorectal cancer treatment must be carefully evaluated through large-scale clinical trials.</Consideration 98-Colorectal cancer treatment outcomes may vary between patients receiving Leucovorin Calcium versus those receiving other treatments, necessitating stratification and biomarker-based monitoring.</Consideration 99
-The role of Leucovorin Calcium in colorectal cancer treatment may be influenced by factors such as tumour histology, stage, and patient demographics, which require consideration in future studies.</Consideration 100-Future research should aim to elucidate the molecular mechanisms underlying Leucovorin Calcium's effects on colorectal cancer, including potential interactions with other targeted therapies or immunotherapies.</Consideration 101-Colorectal cancer treatment guidelines should"
16,Letrozole,Aromatase,"5JL9,5JL7,5JL6,5JKW,5JKV,4GL7,4GL5,3S7S,3S79,3EQM,4KQ8",")<Output>
{{
  ""Mechanism"": ""<Letrozole acts as an aromatase inhibitor, targeting breast cancer cells."",
  ""Pathways"": ""<Aromatase inhibitors like letrozole interfere with estrogen metabolism, leading to increased levels of estrogen in breast cancer cells. This can promote cell growth and survival, contributing to cancer progression."",
  ""Uncertainties"": ""<The exact molecular mechanisms are unclear, but it's believed that letrozole affects estrogen signaling, leading to increased estrogen levels and promoting cancer growth.>""
}}
</Output>

<p>Based on available evidence, letrozole exerts its effects by inhibiting aromatase, the enzyme responsible for converting androgens to estrogens. In breast cancer cells, this inhibition disrupts the estrogen signaling pathway, which promotes cell proliferation and survival. However, the precise molecular mechanisms underlying letrozole's action remain unclear.</p>

</Constraints>

(Note: The provided response is based on the available evidence and understanding up to 2023. For the latest research findings, consult the most recent scientific literature.)"
4,Adenosine triphosphate,Tyrosine-protein kinase ABL1,"5MO4,1OPK,1OPL,2FO0,8SSN,4XEY,6XR7,6XR6,2E2B,4WA9,6NPV,6NPU,6NPE,6HD6,6HD4,4YC8,3UE4,3PYY,3MSS,3MS9,3KFA,3KF4,3K5V,2QOH,2HZN,2G1T,2F4J,1OPJ,1M52,1IEP,1FPU,6XRG,2HIW,4ZOG,3IK3,2Z60,2V7A,3OXZ,7DT2,7CC2,2G2I,2G2H,2G2F,3OY3,3DK6,3DK3,7W7Y,2HZ4,2HYY,8H7H,8H7F,5HU9,8I7Z,8I7T,8I7S,7W7X,3CS9,2HZI,2GQG,7N9G,3QRK,3QRI,3QRJ,2HZ0,4TWP,3DK7,6BL8,3HMI,3GVU,2XYN,4XLI,6AMW,6AMV,2ABL,1ZZP","{""Mechanism"": ""<Adenosine triphosphate (ATP) acts as a signaling molecule that promotes cell growth and survival by activating various downstream pathways in tyrosine-protein kinase ABL1, including the PI3K/AKT/mTOR pathway, which is involved in colorectal cancer."", 
 ""Pathways"": ""<The PI3K/AKT/mTOR pathway is implicated in colorectal cancer, as it regulates cell proliferation, differentiation, and survival. Activation of this pathway can lead to oncogenic effects, including increased cell growth and resistance to apoptosis."", 
 ""Uncertainties"": ""<ATP's role in promoting cell growth and survival may contribute to oncogenesis in colorectal cancer, but its specific mechanisms within ABL1 are not well understood and require further investigation>""}"
9,Dapagliflozin,Sodium/glucose cotransporter 2,"7YNK,7YNJ,7VSI,8HIN,8HG7,8HEZ,8HDH,8HB0",")<Output>
{{
  ""Mechanism"": ""<Dapagliflozin acts by inhibiting sodium-glucose cotransporter 2 (SGLT2) in the kidneys, leading to increased sodium excretion and decreased glucose reabsorption. This results in increased sodium levels in the urine, which increases urine volume and reduces blood pressure. As a result, dapagliflozin lowers blood pressure and reduces the risk of cardiovascular events in patients with type 2 diabetes."",
  ""Pathways"": ""<The primary mechanism of action involves renal sodium and glucose excretion. Increased sodium excretion leads to increased urine volume, which can reduce blood pressure. Additionally, dapagliflozin may have effects on glucose metabolism and insulin sensitivity, but these are not the primary mechanisms of its action."",
  ""Uncertainties"": ""<Uncertainties include the potential for dapagliflozin to affect other metabolic pathways, such as lipid metabolism, and the possibility that its effects on blood pressure may be due to other mechanisms, such as changes in renal function or vascular tone. However, the evidence primarily supports its use in reducing cardiovascular risk in patients with type 2 diabetes and hypertension."">
}}
</Output>

Note: The provided information is based on available scientific evidence up to 01 Mar 2023. For the most recent findings, consult the latest clinical trials, meta-analyses, and reviews."
28,Amphetamine,Trace amine-associated receptor-1,"8JSO,8JLR,8JLQ,8JLP,8JLO,8JLN,8UHB,8ZSS,8ZSP,8ZSJ,8WCA,8WC8,8W8A,8W89,8W88,8W87,9JKQ",")<Output>
{{
  ""Mechanism"": ""<Amphetamine acts by inhibiting serotonin reuptake, leading to increased serotonin levels in the brain."",
  ""Pathways"": ""<Serotonin signaling is implicated in various cancers, including colorectal cancer. The involvement of serotonin in colorectal cancer suggests that the drug may affect colorectal cancer through serotonin-dependent pathways."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Other considerations"": ""<Colorectal cancer may involve complex interactions between multiple signaling pathways, including those related to serotonin, dopamine, and other neurotransmitters. The role of these pathways in colorectal cancer may be influenced by the drug's effects on neurotransmitter systems."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence linking amphetamine to colorectal cancer is limited and inconclusive. Further research is needed to confirm these findings and understand the underlying mechanisms."",
  ""Uncertainties"": ""<The evidence"
41,Glucosamine,Interleukin-1 beta,"5MVZ,7CHZ,7CHY,9ILB,8RZB,8RYS,8RYK,8C3U,7Z4T,7I1B,6Y8M,6Y8I,6I1B,5R8Q,5R8P,5R8O,5R8N,5R8M,5R8L,5R8K,5R8J,5R8I,5R8H,5R8G,5R8F,5R8E,5R8D,5R8C,5R8B,5R8A,5R89,5R88,5R87,5R86,5R85,5R7W,5I1B,5BVP,4I1B,2NVH,2KH2,2I1B,1ITB,1IOB,1I1B,4G6J,4DEP,3O4O,1TWM,1TWE,1TOO,1T4Q,1S0L,41BI,21BI,31BI,1HIB,1TP0,4G6M,1L2H,3LTQ,3POK","{""Mechanism"": ""<Glucosamine acts by inhibiting osteoprotegerin (OPG) which in turn reduces bone resorption., This reduction leads to decreased bone turnover and subsequently decreases the load on the surrounding joints., Furthermore, glucosamine may have anti-inflammatory effects and may help reduce pain and inflammation in patients with osteoarthritis or other joint disorders., However, glucosamine's effects on colorectal cancer are unclear and require further investigation., The evidence for glucosamine's impact on colorectal cancer is limited and inconclusive."", 
 ""Pathways"": ""<The evidence suggests that glucosamine may have potential anti-cancer effects, including anti-proliferative and anti-apoptotic effects., However, more research is needed to confirm these findings and to understand the underlying mechanisms., Colorectal cancer signaling pathways involved include the PI3K/AKT/mTOR pathway and the NF-B pathway., Glucosamine may affect these pathways through various mechanisms, including the inhibition of certain enzymes or the modulation of signaling molecules."", 
 ""Uncertainties"": ""<The evidence for glucosamine's impact on colorectal cancer is limited and inconclusive., More research is needed to confirm these findings and to understand the underlying mechanisms., Uncertainties include the lack of clear evidence for glucosamine's anti-cancer effects in colorectal cancer, the need for further investigation into glucosamine's effects on specific subtypes of colorectal cancer, and the potential for glucosamine to interact with other pathways involved in colorectal cancer progression and metastasis., Additionally, glucosamine may have off-target effects or interact with other pathways involved in colorectal cancer, such as the PI3K/AKT/mTOR pathway or the NF-B pathway, which could lead to uncertainties regarding its overall impact on colorectal cancer.""}
</Output>

Note: Based on the available evidence, it appears that glucosamine may have potential anti-cancer effects, including anti-proliferative and anti-apoptotic effects, but more research is needed to confirm these findings and to understand the underlying mechanisms.

Uncertainties:

* The evidence for glucosamine's impact on colorectal cancer is limited and inconclusive.
* More research is needed to confirm these findings and to understand the underlying mechanisms.
* The lack of clear evidence for glucosamine's anti-cancer effects in colorectal cancer, the need for further investigation into glucosamine's effects on specific subtypes of colorectal cancer, and the potential for glucosamine to interact with other pathways involved in colorectal cancer progression and metastasis, all contribute to uncertainties regarding glucosamine's overall impact on colorectal cancer."
58,Sibutramine,Serotonin transporter,"6VRL,6VRK,6VRH,7TXT,7LWD,5I6Z,6W2C,6W2B,6DZZ,6AWN,7LIA,7LI9,7LI8,7LI6,6AWQ,6AWP,6AWO,5I75,5I74,5I73,5I71,5I6X,7MGW,7LI7,6DZV,6DZY,6DZW,8DE4,8DE3","{""Mechanism"": ""<Sibutramine acts by inhibiting the reuptake of serotonin, thereby increasing the extracellular serotonin concentration. This increase in extracellular serotonin triggers the activation of various signaling pathways, including the PI3K/AKT/mTOR pathway, which is involved in cell proliferation and survival. Additionally, sibutramine may influence the expression of genes involved in cell growth and differentiation, such as EGFRE, which is involved in cell proliferation. Furthermore, sibutramine may affect the activity of certain kinases, such as PKC, which are involved in cell signaling and apoptosis."", 
 ""Pathways"": ""<The increased extracellular serotonin levels activate the PI3K/AKT/mTOR pathway, which is involved in cell proliferation and survival. The PI3K/AKT/mTOR pathway is also involved in cell growth and differentiation, making it a potential target for cancer therapy. Additionally, sibutramine may affect the activity of certain kinases, such as PKC, which are involved in cell signaling and apoptosis., Uncertainties"": ""<Uncertainties regarding the specific molecular mechanisms by which sibutramine exerts its effects on colorectal cancer are unclear. However, it is known that sibutramine can inhibit the reuptake of serotonin, leading to increased extracellular serotonin levels. This increase in extracellular serotonin may trigger the activation of various signaling pathways, including the PI3K/AKT/mTOR pathway. However, the specific molecular mechanisms by which sibutramine exerts its effects on colorectal cancer are not clearly defined.>}
</Output>
2.
The drug binds to the serotonin transporter, which is located on the plasma membrane of intestinal epithelial cells. By inhibiting the reuptake of serotonin, sibutramine increases the extracellular serotonin concentration.

3.
The downstream signalling pathways involved in colorectal cancer are complex and involve multiple pathways. The PI3K/AKT/mTOR pathway is one of the key pathways involved in colorectal cancer. Activation of this pathway leads to increased cell proliferation, survival, and migration, contributing to tumour growth and metastasis.

4.
Uncertainties:
- The exact molecular mechanisms by which sibutramine exerts its effects on colorectal cancer are unclear.
- The involvement of other signalling pathways, such as the PI3K/AKT/mTOR pathway, the MAPK pathway, and the NF-B pathway, in colorectal cancer development and progression.
- The potential role of sibutramine in modulating other pathways involved in colorectal cancer, such as the Wnt/-catenin pathway and the Hippo signaling pathway."
5,Thiazolidinedione,Peroxisome proliferator-activated receptor gamma,"3E00,3DZY,3DZU,7QB1,6L89,6K0T,6AD9,5HZC,5F9B,5DWL,5DVC,5DV8,5DV6,5DV3,5DSH,4PWL,4PVU,4JL4,4JAZ,4E4Q,4E4K,4A4W,4A4V,3R8I,3ADX,3ADW,3ADV,3ADU,3ADT,3ADS,2YFE,8REJ,6ZLY,6T9C,6QJ5,6L8B,6JQ7,6IJR,6F2L,5YCP,5YCN,5LSG,5GTP,5GTO,5GTN,7CXH,7CXG,9HX2,7CXI,4YT1,4O8F,3WMH,3VSP,3VSO,3VJI,3VJH,3HOD,3HO0,3D6D,3CDS,3CDP,3B3K,3AN4,3AN3,2ZNO,2ZK6,2ZK5,2ZK4,2ZK3,2ZK2,2ZK1,2ZK0,2I4Z,2I4P,2I4J,6ENQ,6AN1,3PO9,3PBA,6KTN,6KTM,8C0C,8ADF,7CXK,7CXL,7CXF,1I7I,3VN2,7CXJ,7CXE,3OSW,3OSI,2ZVT,7E0A,1NYX,8ZFT,8ZFS,8ZFR,8ZFQ,8ZFP,8ZFO,8ZFN,8FHG,8FHF,8FHE,8CPJ,8CPI,8CPH,8ATZ,8ATY,7P4E,7AWD,7AWC,7A7H,6Y3U,6VZO,6VZL,6TSG,6T6B,6PDZ,6ONJ,6ONI,6O68,6O67,6MD4,6MD2,6MD1,6MD0,6MCZ,6FZP,6DGO,4R2U,9O9N,9IWK,9CWN,9CK0,8HUP,8HUM,8FKG,8FKF,8FKE,8FKD,8FKC,8B95,8B94,8B93,8B92,8B90,8B8Y,8B8X,8B8W,8AQN,8AQM,7WGQ,7WGP,7WGO,7RLE,6DGQ,6DGL,6AVI,6AUG,4XLD,3TY0,3BC5,2P4Y,1ZEO,6FZG,8U57,7SQB,7SQA,6IJS,6FZJ,6DGR,6DGP,6DCU,6DBH,6D94,6D8X,3R5N,2XKW,1KNU,9L3T,8SC9,8PBO,8HHQ,8HHP,7WOX,7LOT,7EFQ,6JF0,6JEY,6FZY,6FZF,5WR1,5WR0,5WQX,5AZV,4XUM,4XUH,4XTA,3X1I,3X1H,3SZ1,2VV4,2VV3,2VV2,2VV1,2VV0,2VST,2VSR,2OM9,1WM0,8B91,8B8Z,6T1S,3PRG,3B0R,3B0Q,6T1V,6C1I,4R6S,7AHJ,6E5A,5U5L,5TTO,4R06,2Q6S,2Q6R,2Q61,2Q5S,2Q5P,2Q59,6VZN,6VZM,4OJ4,7JQG,7E2O,6MS7,8WFE,8DK4,6ILQ,6ICJ,5TWO,4CI5,3KMG,3K8S,3H0A,3FUR,2POB,1ZGY,1FM9,1FM6,8DSZ,8DSY,8DKV,8DKN,5JI0,2HFP,1K74,9F7X,9F7W,8BFF,8BF2,8BF1,6IZN,6IZM,5Z6S,5Z5S,4F9M,3V9Y,3V9V,3V9T,3T03,3S9S,3LMP,3B1M,5Y2T,5Y2O,3WJ5,3WJ4,6TDC,6DHA,6DH9,6C5T,5UGM,4EMA,4EM9,3QT0,3NOA,3IA6,3GBK,3G9E,3FEJ,3ET3,3ET0,2Q8S,2PRG,2HWR,2HWQ,2GTK,2G0H",")<Output>
{{
  ""Mechanism"": ""<Describe how the drug binds to the target receptor(s) or modulates their activity>"",
  ""Pathways"": ""<Outline the downstream signalling pathways involved in colorectal cancer>"",
  ""Uncertainties"": ""<List any uncertainties or knowledge gaps identified through the analysis>"",
}}
</Output>

<Input>
Drug: Thiazolidinedione
Receptor: Peroxisome proliferator-activated receptor gamma
PDB IDs (if any): 3E00,3DZY,3DZU,7QB1,6L89,6K0T,6AD9,5HZC,5F9B,5DWL,5DVC,5DV6,5DV3,5DSH,4PWL,4PVU,4JL4,4JAZ,4E4Q,4E4K,4A4W,4A4V,3R8I,3ADX,3ADW,3ADV,3ADU,3ADS,2YFE,8REJ,6ZLY,6T9C,6QJ5,6L8B,6JQ7,6IJR,6F2L,5YCP,5YCN,5LSG,5GTP,5GTO,5GTN,7CXH,7CXG,9HX2,7CXI,4YT1,4O8F,3WMH,3VSP,3VSO,3VJI,3HOD,3HO0,3D6D,3CDS,3CDP,3B3K,3AN4,3AN3,2ZNO,2ZK6,2ZK5,2ZK4,2ZK3,2ZK2,2ZK1,2ZK0,2I4Z,2I4P,2I4J,6ENQ,6AN1,3PO9,3PBA,6KTN,6KTM,8C0C,8ADF,7CXK,7CXE,3OSW,3OSI,2ZVT,7E0A,1NYX,8ZFT,8ZFP,8ZFR,8ZFQ,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8ZFP,8"
61,Trimethoprim,Dihydrofolate reductase,"8WGN,7XI7,6DAV,5SDB,5SDA,5SD9,5SD8,5SD7,5SD6,4M6L,4M6K,4M6J,3GYF,3FS6,2W3M,2W3B,2W3A,1MVT,1MVS,6VCJ,7ESE,3GI2,3F8Y,6DE4,6A7E,6A7C,5HVE,5HVB,5HUI,5HT5,5HT4,5HSU,5HSR,5HQZ,5HQY,5HPB,4QJC,4QHV,4KFJ,4KEB,4KD7,4KBN,4KAK,4G95,4DDR,3S7A,3NZD,3NXY,3NXX,3NXV,3NXT,3NXR,3NU0,3NTZ,3GHW,2DHF,2C2T,2C2S,1YHO,1U72,1S3W,1S3V,1S3U,1PDB,1PD9,1PD8,1OHK,1OHJ,1KMV,1KMS,1HFR,1DRF,1DHF,3NXO,3F8Z,3L3R,1DLR,1DLS,1U71,1HFQ,3F91,1HFP,1BOZ,3GHC,3EIG,3S3V,3GHV,3OAF,3N0H,3K47,3D84,3D80,2FZJ,3K45,1U70",")<Output format>
{{
  ""Mechanism"": ""<Trimethoprim acts by inhibiting dihydrofolate reductase (DHFR) in bacteria, which is crucial for DNA synthesis and repair."",
  ""Pathways"": ""<Colorectal cancer signaling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Uncertainties"": ""<Unclear whether trimethoprim directly targets DHFR or if it affects downstream pathways such as PI3K/AKT/mTOR signaling, which are also implicated in colorectal cancer."",
  ""Conflicts"": ""<Conflict with known evidence suggesting trimethoprim may have anti-tumour effects through other mechanisms such as modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  ""Conflicts"": ""<Conflict with evidence suggesting trimethoprim may have anti-cancer effects through modulating the immune response or affecting DNA repair pathways."",
  ""Uncertainties"": ""<Unclear whether trimethoprim's effects on colorectal cancer are primarily due to its impact on DHFR or if other pathways contribute to tumour growth and metastasis."",
  ""Mechanisms"": ""<Trimethoprim's anti-cancer effects may involve modulating the immune response, affecting DNA repair pathways, or influencing tumour cell metabolism and angiogenesis."",
  ""Pathways"": ""<Colorectal cancer signalling involves DHFR inhibition leading to increased S-phase duration and DNA damage, contributing to tumour progression and metastasis."",
  """
12,Panitumumab,Epidermal growth factor receptor,"7SZ7,7SZ5,7SYE,7SYD,7SZ1,7SZ0,8HGS,8HGP,8HGO,5XWD,3QWQ,7OM4,1IVO,4UV7,9IPE,9IPD,9IPC,9IPB,9IPA,9IP9,9IP8,9IP7,4KRO,3B2V,1NQL,4KRP,1YY9,6ARU,3NJP,4UIP,1MOX,5WB8,5WB7,7LFR,7LEN,7LFS,3GOP,8UKV,8UKX,8UKW,5CNN,5ZWJ,4RIY,4RIX,4RIW,8HV2,7AEM,8TJL,8F1Z,8F1Y,8F1X,8F1H,7U9A,7U99,7KXZ,4ZJV,7SI1,7B85,5EM8,5CZI,5CZH,5CAV,4WD5,4R5S,4LQM,3IKA,1M17,1M14,4TKS,7UKV,3VJO,8PNZ,7AEI,5UGB,4I23,1XKK,4LL0,9H46,9GL9,9GI9,9FRD,8SC7,8G63,6VHP,6VHN,6VH4,6D8E,5Y9T,4ZAU,4WRG,4WKQ,4G5J,3W33,3W32,3W2S,3POZ,2RF9,2J6M,2J5F,2J5E,2ITY,2ITX,2ITW,2GS6,2GS2,2EB2,7T4I,5XDL,5FED,2JIV,2JIU,9GDV,9GC6,9GC5,9FZS,9FZR,9BY6,9BY4,8PO4,8PO3,4I24,2EB3,4LRM,5X2K,4G5P,2JIT,8GK5,8GB4,8F1W,8EME,7U98,7LTX,7LG8,7KY0,7JXW,7JXQ,7JXP,7JXM,7JXL,7JXK,7JXI,6JZ0,6JX4,6JX0,6DUK,5YU9,5XGM,5XDK,5X2F,5X2C,5X2A,5X28,5X27,5X26,5GTZ,5GTY,5GMP,5FEQ,5FEE,5D41,4ZSE,3VJN,3UG2,3UG1,2ITZ,2ITV,2ITU,2ITT,2ITQ,2ITP,2ITO,2ITN,8TO4,8TO3,8FV4,8FV3,7UKW,6XL4,6WXN,6WAK,6WA2,6V5P,6V5N,6JWL,5CNO,4I21,3GT8,2GS7,7ZYQ,7A6K,7A6J,7A6I,7A2A,6Z4D,6Z4B,6TG1,6TG0,6TFZ,6TFY,6TFW,6TFV,6TFU,4JRV,4JR3,4JQ8,4JQ7,8H7X,8DSW,7K1I,7K1H,6JRX,5ZTO,5XGN,5JEB,4HJO,8PO0,4I20,4LI5,6V6O,6V6K,6V66,6P8Q,6P1L,6P1D,9DF2,8D76,8D73,5UWD,5UGC,5UGA,5UG9,5UG8,5U8L,5HG9,5HG8,5HG7,5HG5,4I22,4I1Z,9JQ1,9DF4,9DF3,6JXT,6JRK,5J9Z,9HBO,9GC4,9EWT,9EWS,8PO2,8PO1,9GL8,9GL7,9FQS,9FQP,7ZYP,7ZYN,7ZYM,6S8A,6S89,8A2A,8A27,8HY7,7T4J,7LGS,8HV5,8HV3,8HV1,7OXB,5Y25,5HIC,5HIB,5HCZ,5HCY,5HCX,5EM7,5EM6,5EM5","(""<Output format>
{{
  ""Mechanism"": ""<Describe the binding or modulation of the receptor>"",
  ""Pathways"": ""<Summarize the downstream signalling pathways involved in colorectal cancer>"",
  ""Uncertainties"": ""<Note any unclear or conflicting mechanisms>"",
}}
</Output format>""

<Input>
Drug: Panitumumab
Receptor: Epidermal growth factor receptor
PDB IDs (if any): 7SZ7,7SZ5,7SYE,7SYD,7SZ1,7SZ0,8HGS,8HGP,8HGO,5XWD,5XWD2,5XWD1,5XWD0,4ZSE,4ZSV,4ZSU,4ZSU2,4ZSU3,4ZSU4,4ZSU5,4ZSU6,4ZSU7,4ZSU8,4ZSU9,4ZSU10,4ZSU11,4ZSU12,4ZSU13,4ZSU14,4ZSU15,4ZSU16,4ZSU17,4ZSU18,4ZSU19,4ZSU20,4ZSU21,4ZSU22,4ZSU23,4ZSU24,4ZSU25,4ZSU26,4ZSU27,4ZSU28,4ZSU29,4ZSU30,4ZSU31,4ZSU32,4ZSU33,4ZSU34,4ZSU35,4ZSU36,4ZSU37,4ZSU38,4ZSU39,4ZSU40,4ZSU41,4ZSU42,4ZSU43,4ZSU44,4ZSU45,4ZSU46,4ZSU47,4ZSU48,4ZSU49,4ZSU50,4ZSU51,4ZSU52,4ZSU53,4ZSU54,4ZSU55,4ZSU56,4ZSU57,4ZSU58,4ZSU59,4ZSU60,4ZSU61,4ZSU62,4ZSU63,4ZSU64,4ZSU65,4ZSU66,4ZSU67,4ZSU68,4ZSU69,4ZSU70,4ZSU71,4ZSU72,4ZSU73,4ZSU74,4ZSU75,4ZSU76,4ZSU77,4ZSU78,4ZSU79,4ZSU80,4ZSU81,4ZSU82,4ZSU83,4ZSU84,4ZSU85,4ZSU86,4ZSU87,4ZSU88,4ZSU89,4ZSU90,4ZSU91,4ZSU92,4ZSU93,4ZSU94,4ZSU95,4ZSU96,4ZSU97,4ZSU98,4ZSU99,4ZSU100,4ZSU101,4ZSU102,4ZSU103,4ZSU104,4ZSU105,4ZSU106,4ZSU107,4ZSU108,4ZSU109,4ZSU110,4ZSU111,4ZSU112,4ZSU113,4ZSU114,4ZSU115,4ZSU116,4ZSU117,4ZSU118,4ZSU119,4ZSU120,4ZSU121,4ZSU122,4ZSU123,4ZSU124,4ZSU125,4ZSU126,4ZSU127,4ZSU128,4ZSU129,4ZSU130,4ZSU131,4ZSU132,4ZSU133,4ZSU134,4ZSU135,4ZSU136,4ZSU137,4ZSU138,4ZSU139,4ZSU140,4ZSU141,4ZSU142,4ZSU143,4ZSU144,4ZSU145,4ZSU146,4ZSU147,4ZSU148,4ZSU149,4ZSU150,4ZSU151,4ZSU152,4ZSU153,4ZSU154,4ZSU155,4ZSU156,4ZSU157,4ZSU158,4ZSU159,4ZSU160,4ZSU161,4ZSU162,4ZSU163,4ZSU164,4ZSU165,4ZSU166,4ZSU167,4ZSU168,4ZSU169,4ZSU170,4ZSU171,4ZSU172,4ZSU173,4ZSU174,4ZSU175,4ZSU176,4ZSU177,4ZSU178,4ZSU179,4ZSU180,4ZSU181,4ZSU182,4ZSU183,4ZSU184,4ZSU185,4ZSU186,4ZSU187,4ZSU188,4ZSU189,4ZSU190,4ZSU191,4ZSU192,4ZSU193,4ZSU194,4ZSU195,4ZSU196,4ZSU197,4ZSU198,4ZSU199,4ZSU200,4ZSU201,4ZSU202,4ZSU203,4ZSU204,4ZSU205,4ZSU206,4ZSU207,4ZSU208,4ZSU209,4ZSU210,4ZSU211,4ZSU212,4ZSU213,4ZSU214,4ZSU215,4ZSU216,4ZSU217,4ZSU218,4ZSU219,4ZSU220,4ZSU221,4ZSU222,4ZSU223,4ZSU224,4ZSU225,4ZSU226,4ZSU227,4ZSU228,4ZSU229,4ZSU230,4ZSU231,4ZSU232,4ZSU233,4ZSU234,4ZSU235,4ZSU236,4ZSU237,4ZSU238,4ZSU239,4ZSU240,4ZSU241,4ZSU242,4ZSU243,4ZSU244,4ZSU245,4ZSU246,4ZSU247,4ZSU248,4ZSU249,4ZSU250,4ZSU251,4ZSU252,4ZSU253,4ZSU254,4ZSU255,4ZSU256,4ZSU257,4ZSU258,4ZSU259,4ZSU260,4ZSU261,4ZSU262,4ZSU263,4ZSU264,4ZSU265,4ZSU266,4ZSU267,4ZSU268,4ZSU269,4ZSU270,4ZSU271,4ZSU272,4ZSU273,4ZSU274,4ZSU275,4ZSU276,4ZSU277,4ZSU278,4ZSU279,4ZSU280,4ZSU281,4ZSU282,4ZSU283,4ZSU284,4ZSU285,4ZSU286,4ZSU287,4ZSU288,4ZSU289,4ZSU290,4ZSU291,4ZSU292,4ZSU293,4ZSU294,4ZSU295,4ZSU296,4ZSU297,4ZSU298,4ZSU299,4ZSU300,4ZSU301,4ZSU302,4ZSU303,4ZSU304,4ZSU305,4ZSU306,4ZSU307,4ZSU308,4ZSU309,4ZSU310,4ZSU311,4ZSU312,4ZSU313,4ZSU314,4ZSU315,4ZSU316,4ZSU317,4ZSU318,4ZSU319,4ZSU320,4ZSU321,4ZSU322,4ZSU323,4ZSU324,4ZSU325,4ZSU326,4ZSU327,4ZSU328,4ZSU329,4ZSU330,4ZSU331,4ZSU332,4ZSU333,4ZSU334,4ZSU335,4ZSU336,4ZSU337,4ZSU338,4ZSU339,4ZSU340,4ZSU341,4ZSU342,4ZSU343,4ZSU344,4ZSU345,4ZSU346,4ZSU347,4ZSU348,4ZSU349,4ZSU350,4ZSU351,4ZSU352,4ZSU353,4ZSU354,4ZSU355,4ZSU356,4ZSU357,4ZSU358,4ZSU359,4ZSU360,4ZSU361,4ZSU362,4ZSU363,4ZSU364,4ZSU365,4ZSU366,4ZSU367,4ZSU368,4ZSU369,4ZSU370,4ZSU371,4ZSU372,4ZSU373,4ZSU374,4ZSU375,4ZSU376,4ZSU377,4ZSU378,4ZSU379,4ZSU380,4ZSU381,4ZSU382,4ZSU383,4ZSU384,4ZSU385,4ZSU386,4ZSU387,4ZSU388,4ZSU389,4ZSU390,4ZSU391,4ZSU392,4ZSU393,4ZSU394,4ZSU395,4ZSU396,4ZSU397,4ZSU398,4ZSU399,4ZSU400,4ZSU401,4ZSU402,4ZSU403,4ZSU404,4ZSU405,4ZSU406,4ZSU407,4ZSU408,4ZSU409,4ZSU410,4ZSU411,4ZSU412,4ZSU413,4ZSU414,4ZSU415,4ZSU416,4ZSU417,4ZSU418,4ZSU419,4ZSU420,4ZSU421,4ZSU422,4ZSU423,4ZSU424,4ZSU425,4ZSU426,4ZSU427,4ZSU428,4ZSU429,4ZSU430,4ZSU431,4ZSU432,4ZSU433,4ZSU434,4ZSU435,4ZSU436,4ZSU437,4ZSU438,4ZSU439,4ZSU440,4ZSU441,4ZSU442,4ZSU443,4ZSU444,4ZSU445,4ZSU446,4ZSU447,4ZSU448,4ZSU449,4ZSU450,4ZSU451,4ZSU452,4ZSU453,4ZSU454,4ZSU455,4ZSU456,4ZSU457,4ZSU458,4ZSU459,4ZSU460,4ZSU461,4ZSU462,4ZSU463,4ZSU464,4ZSU465,4ZSU466,4ZSU467,4ZSU468,4ZSU469,4ZSU470,4ZSU471,4ZSU472,4ZSU473,4ZSU474,4ZSU475,4ZSU476,4ZSU477,4ZSU478,4ZSU479,4ZSU480,4ZSU481,4ZSU482,4ZSU483,4ZSU484,4ZSU485,4ZSU486,4ZSU487,4ZSU488,4ZSU489,4ZSU490,4ZSU491,4ZSU492,4ZSU493,4ZSU494,4ZSU495,4ZSU496,4ZSU497,4ZSU498,4ZSU499,4ZSU500,4ZSU501,4ZSU502,4ZSU503,4ZSU504,4ZSU505,4ZSU506,4ZSU507,4ZSU508,4ZSU509,4ZSU510,4ZSU511,4ZSU512,4ZSU513,4ZSU514,4ZSU515,4ZSU516,4ZSU517,4ZSU518,4ZSU519,4ZSU520,4ZSU521,4ZSU522,4ZSU523,4ZSU524,4ZSU525,4ZSU526,4ZSU527,4ZSU528,4ZSU529,4ZSU530,4ZSU531,4ZSU532,4ZSU533,4ZSU534,4ZSU535,4ZSU536,4ZSU537,4ZSU538,4ZSU539,4ZSU540,4ZSU541,4ZSU542,4ZSU543,4ZSU544,4ZSU545,4ZSU546,4ZSU547,4ZSU548,4ZSU549,4ZSU550,4ZSU551,4ZSU552,4ZSU553,4ZSU554,4ZSU555,4ZSU556,4ZSU557,4ZSU558,4ZSU559,4ZSU560,4ZSU561,4ZSU562,4ZSU563,4ZSU564,4ZSU565,4ZSU566,4ZSU567,4ZSU568,4ZSU569,4ZSU570,4ZSU571,4ZSU572,4ZSU573,4ZSU574,4ZSU575,4ZSU576,4ZSU577,4ZSU578,4ZSU579,4ZSU580,4ZSU581,4ZSU582,4ZSU583,4ZSU584,4ZSU585,4ZSU586,4ZSU587,4ZSU588,4ZSU589,4ZSU590,4ZSU591,4ZSU592,4ZSU593,4ZSU594,4ZSU595,4ZSU596,4ZSU597,4ZSU598,4ZSU599,4ZSU600,4ZSU601,4ZSU602,4ZSU603,4ZSU604,4ZSU605,4ZSU606,4ZSU607,4ZSU608,4ZSU609,4ZSU610,4ZSU611,4ZSU612,4ZSU613,4ZSU614,4ZSU615,4ZSU616,4ZSU617,4ZSU618,4ZSU619,4ZSU620,4ZSU621,4ZSU622,4ZSU623,4ZSU624,4ZSU625,4ZSU626,4ZSU627,4ZSU628,4ZSU629,4ZSU630,4ZSU631,4ZSU632,4ZSU633,4ZSU634,4ZSU635,4ZSU636,4ZSU637,4ZSU638,4ZSU639,4ZSU640,4ZSU641,4ZSU642,4ZSU643,4ZSU644,4ZSU645,4ZSU646,4ZSU647,4ZSU648,4ZSU649,4ZSU650,4ZSU651,4ZSU652,4ZSU653,4ZSU654,4ZSU655,4ZSU656,4ZSU657,4ZSU658,4ZSU659,4ZSU660,4ZSU661,4ZSU662,4ZSU663,4ZSU664,4ZSU665,4ZSU666,4ZSU667,4ZSU668,4ZSU669,4ZSU670,4ZSU671,4ZSU672,4ZSU673,4ZSU674,4ZSU675,4ZSU676,4ZSU677,4ZSU678,4ZSU679,4ZSU680,4ZSU681,4ZSU682,4ZSU683,4ZSU684,4ZSU685,4ZSU686,4ZSU687,4ZSU688,4ZSU689,4ZSU690,4ZSU691,4ZSU692,4ZSU693,4ZSU694,4ZSU695,4ZSU696,4ZSU697,4ZSU698,4ZSU699,4ZSU700,4ZSU701,4ZSU702,4ZSU703,4ZSU704,4ZSU705,4ZSU706,4ZSU707,4ZSU708,4ZSU709,4ZSU710,4ZSU711,4ZSU712,4ZSU713,4ZSU714,4ZSU715,4ZSU716,4ZSU717,4ZSU718,4ZSU719,4ZSU720,4ZSU721,4ZSU722,4ZSU723,4ZSU724,4ZSU725,4ZSU726,4ZSU727,4ZSU728,4ZSU729,4ZSU730,4ZSU731,4ZSU732,4ZSU733,4ZSU734,4ZSU735,4ZSU736,4ZSU737,4ZSU738,4ZSU739,4ZSU740,4ZSU741,4ZSU742,4ZSU743,4ZSU744,4ZSU745,4ZSU746,4ZSU747,4ZSU748,4ZSU749,4ZSU750,4ZSU751,4ZSU752,4ZSU753,4ZSU754,4ZSU755,4ZSU756,4ZSU757,4ZSU758,4ZSU759,4ZSU760,4ZSU761,4ZSU762,4ZSU763,4ZSU764,4ZSU765,4ZSU766,4ZSU767,4ZSU768,4ZSU769,4ZSU770,4ZSU771,4ZSU772,4ZSU773,4ZSU774,4ZSU775,4ZSU776,4ZSU777,4ZSU778,4ZSU779,4ZSU780,4ZSU781,4ZSU782,4ZSU783,4ZSU784,4ZSU785,4ZSU786,4ZSU787,4ZSU788,4ZSU789,4"
25,Albiglutide,Glucagon-like peptide 1 receptor,"7FIM,7RTB,9J1P,9IVM,9IVG,9EBQ,9EBO,9EBN,9C0K,9BYO,8YWF,8YW3,8WG7,8JIR,8JIP,7VBI,7VBH,7S3I,7S1M,7LLY,7LLL,7LCK,7LCJ,7LCI,7KI1,7KI0,7EVM,7E14,7DUR,7DUQ,7C2E,6X1A,6X19,6X18,6ORV,6B3J,7X8S,7X8R,7RGP,7RG9,6XOX,6VCB,5NX2,8JIS,7S15,6LN2,5VAI,6KK7,6KK1,6KJV,5VEX,5VEW,6GB1,5E94,3IOL,4ZGM,3C5T,3C59,5OTX,5OTW,5OTV,5OTU,5OTT","{""Mechanism"": ""<Albiglutide targets the glucagon-like peptide 1 receptor but does not directly interact with it, nor does it inhibit its activity. Instead, it may influence the signaling pathways that are downstream of the glucagon-like peptide 1 receptor., The downstream signalling pathways involved in colorectal cancer include the PI3K/AKT/mTOR pathway, the MAPK pathway, and the NF-B pathway., Uncertainties"": ""<No clear evidence links Albiglutide to colorectal cancer treatment outcomes or to specific molecular pathways involved in colorectal cancer.>""}

{""Pathways"": ""<The PI3K/AKT/mTOR pathway, the MAPK pathway, and the NF-B pathway are all implicated in colorectal cancer progression. The PI3K/AKT/mTOR pathway is involved in cell proliferation, survival, and migration., The MAPK pathway is involved in cell proliferation, differentiation, and apoptosis., The NF-B pathway is involved in inflammation, immune response, and cell survival., Uncertainties"": ""<There is limited evidence linking Albiglutide to the inhibition of specific molecular pathways involved in colorectal cancer treatment outcomes or to the modulation of these pathways in colorectal cancer patients.>""}

)<Note>: Albiglutide has been investigated for its potential to treat or prevent colorectal cancer. However, the evidence is mostly based on preclinical studies and clinical trials with small cohorts of patients. Further research is needed to confirm its efficacy and safety in treating colorectal cancer."
65,Vildagliptin,Dipeptidyl peptidase 4,"2QTB,2QT9,2BGR,2JID,3F8S,2QJR,3W2T,3VJM,3VJL,3VJK,1WCY,1J2E,3QBJ,1PFQ,4PV7,8ZDX,2RIP,9JMM,9JMJ,5Y7K,5Y7J,5Y7H,4LKO,4L72,4JH0,4J3J,4DTC,4DSZ,4DSA,3OC0,3KWJ,3KWF,3H0C,3EIO,3BJM,2OQI,2OLE,2OGZ,2BUB,2BGN,2AJL,1W1I,1TKR,1TK3,1RWQ,1NU8,1NU6,1N1M,8WKU,4QZV,3SX4,3SWW,3Q0T,3NOX,2RGU,1R9N,9GOH,5KBY,4KR0,4G1F,3OPM,3O9V,3O95,3G0G,3G0D,3G0C,3G0B,3CCC,3CCB,1U8E,1R9M,3WQH,6B1O,6B1E,5T4H,5T4F,5T4E,5T4B,5ISM,5I7U,4PNZ,4N8E,4N8D,4A5S,3HAC,3HAB,3D4L,3C45,3C43,2QOE,2QKY,2P8S,2OPH,2IIV,2IIT,2HHA,2FJP,1X70,2ONC,5ZID,5J3J,2OQV,2OAG,2I78,2I03,2G63,2G5T,2G5P,3Q8W,9LBT,5LLS,8ZE6,7XNM,2BUC,2BUA,2AJD,2AJC,2AJB,2AJ8,1ORW,1ORV","<Output>
{{
  ""Mechanism"": ""<Vildagliptin targets Dipeptidyl peptidase 4 (DPP-4) in the liver and pancreas, but its role in colorectal cancer is less clear."",
  ""Pathways"": ""<Colorectal cancer signalling involves insulin/IGF-1 receptor, AMPK, mTOR, PI3K/AKT, and NF-B pathways, but the involvement of DPP-4 is still uncertain."",
  ""Uncertainties"": ""<The evidence suggests that Vildagliptin may have anti-cancer effects, but the specific mechanisms by which it exerts these effects are unclear, particularly in colorectal cancer."",
  ""Other considerations"": ""<Further research is needed to fully understand the role of Vildagliptin in colorectal cancer, including its potential anti-cancer effects and any potential interactions with other pathways involved in cancer."",
  ""Unclear or conflicting findings"": ""<There are no clear or conflicting findings regarding the role of Vildagliptin in colorectal cancer, but ongoing research may provide further insights into its potential anti-cancer effects."",
  ""Insufficient evidence"": ""<Insufficient evidence exists to support the claim that Vildagliptin has a significant impact on colorectal cancer, and more research is needed to fully understand its role in this disease."",
  ""Unknown mechanisms"": ""<The exact mechanisms by which Vildagliptin may exert its anti-cancer effects in colorectal cancer are unclear, and further research is needed to fully understand its role in this disease."",
  ""Unclear relevance"": ""<Vildagliptin's relevance to colorectal cancer may be unclear, and more research is needed to fully understand its potential anti-cancer effects in this disease."",
  ""Unclear relevance to other cancers"": ""<Vildagliptin's relevance to other cancers may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer effects in these diseases."",
  ""Unclear relevance to other diseases"": ""<Vildagliptin's relevance to other diseases may be unclear, and more research is needed to fully understand its potential anti-cancer"
47,Linagliptin,Dipeptidyl peptidase 4,"2QTB,2QT9,2BGR,2JID,3F8S,2QJR,3W2T,3VJM,3VJL,3VJK,1WCY,1J2E,3QBJ,1PFQ,4PV7,8ZDX,2RIP,9JMM,9JMJ,5Y7K,5Y7J,5Y7H,4LKO,4L72,4JH0,4J3J,4DTC,4DSZ,4DSA,3OC0,3KWJ,3KWF,3H0C,3EIO,3BJM,2OQI,2OLE,2OGZ,2BUB,2BGN,2AJL,1W1I,1TKR,1TK3,1RWQ,1NU8,1NU6,1N1M,8WKU,4QZV,3SX4,3SWW,3Q0T,3NOX,2RGU,1R9N,9GOH,5KBY,4KR0,4G1F,3OPM,3O9V,3O95,3G0G,3G0D,3G0C,3G0B,3CCC,3CCB,1U8E,1R9M,3WQH,6B1O,6B1E,5T4H,5T4F,5T4E,5T4B,5ISM,5I7U,4PNZ,4N8E,4N8D,4A5S,3HAC,3HAB,3D4L,3C45,3C43,2QOE,2QKY,2P8S,2OPH,2IIV,2IIT,2HHA,2FJP,1X70,2ONC,5ZID,5J3J,2OQV,2OAG,2I78,2I03,2G63,2G5T,2G5P,3Q8W,9LBT,5LLS,8ZE6,7XNM,2BUC,2BUA,2AJD,2AJC,2AJB,2AJ8,1ORW,1ORV","<Output>
{{
  ""Mechanism"": ""<Linagliptin targets Dipeptidyl peptidase 4 (DPP4) in the liver and pancreatic islet cells."",
  ""Pathways"": ""<DPP4 inhibition reduces glucose levels and improves glycemic control."",
  ""Uncertainties"": ""<Uncertainty regarding potential effects on the gut microbiome and metabolic disorders>""
}}
</Output>

Explanation:
Linagliptin targets Dipeptidyl peptididase 4 (DPP4), which is involved in glucose metabolism. By inhibiting DPP4, linagliptin reduces glucose levels and improves glycemic control. This action is expected to benefit patients with type 2 diabetes and those with obesity-related type 2 diabetes mellitus.

The downstream signalling pathways involved in colorectal cancer include:

- The PI3K/AKT/mTOR pathway, which is activated by DPP4 inhibition and promotes cell proliferation and survival.
- The AMPK/mTORC1/mTORC2/PI3K/AKT pathway, which is also activated by DPP4 inhibition and plays a role in regulating glucose metabolism and cell growth.
- The NF-B pathway, which is involved in inflammation and tumour progression.

Uncertainties:
- The specific mechanisms by which linagliptin exerts its anti-colorectal cancer effects are unclear.
- The potential effects of DPP4 inhibition on the gut microbiome and metabolic disorders are uncertain.
- The involvement of other signalling pathways, such as the PI3K/AKT/mTOR pathway, in colorectal cancer is still being researched and understood."
0,Metformin,Acetyl-CoA carboxylase 2,"3FF6,3TDC,2X24,3JRX,3JRW,2HJW,4HQ6,5KKN,3GLK,3GID,2DN8",")<Output>
{{
  ""Mechanism"": ""<Metformin targets acetyl-CoA carboxylase 2 (ACC2) in the glycolytic pathway, which is crucial for cellular energy production. By inhibiting ACC2, metformin reduces glucose availability, leading to decreased ATP production and subsequent metabolic shifts that favor gluconeogenesis."",
  ""Pathways"": ""<Metformin's action on the glycolytic pathway, which is vital for energy homeostasis, and its potential impact on colorectal cancer through altered metabolic states."",
  ""Uncertainties"": ""<Uncertainty regarding the direct link between metformin's metabolic effects and colorectal cancer outcomes; however, evidence suggests metformin may have a protective effect against colorectal cancer through metabolic alterations."",
  ""Other"":
    ""<Metformin has been studied in various cancers, including colorectal cancer; however, findings are mixed, and more research is needed to fully understand its role."",
    ""<Colorectal cancer treatment outcomes are complex and multifactorial; metformin may have benefits in some contexts but is not a standard treatment."",
    ""<The evidence linking metformin directly to improved colorectal cancer outcomes is limited; further research is required to establish a causal relationship."",
    ""<Metformin's use in colorectal cancer is primarily driven by its established role in diabetes management and obesity treatment."",
    ""<More research is needed to fully understand metformin's role in colorectal cancer; however, it may be considered for patients with severe metabolic disorders."",
  ""Other"">
  </Outcomes>
}</Input>

<Constraints>
  ""<Metformin's exact mechanisms of action in colorectal cancer are unclear; however, evidence suggests it may have a protective effect through metabolic alterations."",
  ""<More research is needed to establish a causal relationship between metformin and improved colorectal cancer outcomes."",
  ""<Metformin may be considered for patients with severe metabolic disorders; however, its role in colorectal cancer is primarily driven by its established use in diabetes management and obesity treatment."",
  ""<The evidence linking metformin directly to improved colorectal cancer outcomes is limited; further research is required to establish a causal relationship."",
  ""<Metformin's use in colorectal cancer is primarily driven by its established role in diabetes management and obesity treatment."",
  ""<More research is needed to fully understand metformin's role in colorectal cancer; however, it may be considered for patients with severe metabolic disorders."",
</Constraints>"
